132 related articles for article (PubMed ID: 23303712)
1. The determinants of pricing in pharmaceuticals: are US prices really so high?
Cabrales A; Jiménez-Martín S
Health Econ; 2013 Nov; 22(11):1377-97. PubMed ID: 23303712
[TBL] [Abstract][Full Text] [Related]
2. Implications of external price referencing of pharmaceuticals in Middle East countries.
Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
[TBL] [Abstract][Full Text] [Related]
3. Differential pricing of new pharmaceuticals in lower income European countries.
Kaló Z; Annemans L; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
[TBL] [Abstract][Full Text] [Related]
4. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings.
Russo G; McPake B
Health Policy Plan; 2010 Jan; 25(1):70-84. PubMed ID: 19843636
[TBL] [Abstract][Full Text] [Related]
5. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
[TBL] [Abstract][Full Text] [Related]
6. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
Danzon PM
Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
[TBL] [Abstract][Full Text] [Related]
7. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
8. Comparative Approaches to Drug Pricing.
Kang SY; Bai G; DiStefano MJ; Socal MP; Yehia F; Anderson GF
Annu Rev Public Health; 2020 Apr; 41():499-512. PubMed ID: 31874070
[TBL] [Abstract][Full Text] [Related]
9. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
10. The level of income appears to have no consistent bearing on pharmaceutical prices across countries.
Morel CM; McGuire A; Mossialos E
Health Aff (Millwood); 2011 Aug; 30(8):1545-52. PubMed ID: 21821572
[TBL] [Abstract][Full Text] [Related]
11. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
Martikainen J; Kivi I; Linnosmaa I
Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
[TBL] [Abstract][Full Text] [Related]
12. Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United States.
Roughead EE; Lopert R; Sansom LN
Value Health; 2007; 10(6):514-20. PubMed ID: 17970935
[TBL] [Abstract][Full Text] [Related]
13. Effects of regulation on drug launch and pricing in interdependent markets.
Danzon PM; Epstein AJ
Adv Health Econ Health Serv Res; 2012; 23():35-71. PubMed ID: 23156660
[TBL] [Abstract][Full Text] [Related]
14. Prices of pharmaceuticals in poor countries are much lower than in wealthy countries.
Schweitzer SO; Comanor WS
Health Aff (Millwood); 2011 Aug; 30(8):1553-61. PubMed ID: 21821573
[TBL] [Abstract][Full Text] [Related]
15. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
Stargardt T; Schreyögg J; Busse R
Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
[TBL] [Abstract][Full Text] [Related]
16. Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
Carapinha JL
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):11-4. PubMed ID: 26707161
[TBL] [Abstract][Full Text] [Related]
17. International prices and availability of pharmaceuticals in 2005.
Danzon PM; Furukawa MF
Health Aff (Millwood); 2008; 27(1):221-33. PubMed ID: 18180499
[TBL] [Abstract][Full Text] [Related]
18. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
19. Determinants of branded prescription medicine prices in OECD countries.
Kanavos PG; Vandoros S
Health Econ Policy Law; 2011 Jul; 6(3):337-67. PubMed ID: 21676345
[TBL] [Abstract][Full Text] [Related]
20. Review of studies reporting actual prices for medicines.
Mardetko N; Kos M; Vogler S
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
